About Berry Flavonoid Pigments
Anthocyanins are the red/purple/blue flavonoid pigments in berries and fruits — the largest group of water-soluble plant pigments. Over 700 individual compounds exist; different berries deliver very different profiles (bilberry ≠ blueberry ≠ aronia ≠ blackcurrant). Multiple meta-analyses show consistent modest lipid improvements: LDL ↓5 mg/dL, TG ↓6 mg/dL, HDL ↑11 mg/dL. Significant acute and chronic FMD improvement. Uniquely strong epidemiological CVD signal — anthocyanins are the only flavonoid subclass significantly associated with lower CHD, CVD, and total mortality in large prospective cohort studies (Iowa Women's Health Study, NHS+HPFS). However, no RCT has tested hard CVD endpoints. ⚠️ Only ~1% reaches circulation as intact anthocyanin (~12% true bioavailability counting all metabolites). Effects likely mediated by gut microbial metabolites, creating massive inter-individual variability. Blood pressure and inflammation benefits appear stronger with whole berries than isolated anthocyanins (synergy with other polyphenols). Eye health/night vision claims — the most commercially exploited application — have the weakest evidence. Exceptionally safe; no serious adverse effects at any supplemental dose.
What Berry Flavonoid Pigments supports
- Consistent modest lipid improvement across meta-analyses (LDL ↓, TG ↓, HDL ↑) and strong epidemiological CVD association
- Improves vascular function (FMD) acutely and chronically via nitric oxide enhancement
- Only ~1% bioavailable as intact compound — effects depend heavily on individual gut microbiome and berry source
How much Berry Flavonoid Pigments to take
Clinical studies typically use 80–500 mg of Berry Flavonoid Pigments. General cardiovascular: 80–500 mg/day anthocyanins. Glycemic effects require >300 mg/day for >8 weeks. Bilberry eye products typically provide 36–160 mg/day anthocyanins. Purified supplements (e.g. Medox 80 mg) have the most targeted lipid data.
- Effective range
- 80–500 mg
Clinical evidence
Moderate clinical evidence. Multiple meta-analyses show consistent modest lipid improvements; strong epidemiological CVD signal
NIH Fact Sheet